UBS analyst Colin Bristow upgrades Pfizer (NYSE:PFE) from Neutral to Buy and raises the price target from $52 to $60.UBS analyst Colin Bristow upgrades Pfizer (NYSE:PFE) from Neutral to Buy and raises the price target from $52 to $60.